Gene expression and 18FDG uptake in atherosclerotic carotid plaques. 2010

Sune Folke Pedersen, and Martin Graebe, and Anne Mette Fisker Hag, and Liselotte Højgaard, and Henrik Sillesen, and Andreas Kjaer
Cluster for Molecular Imaging, Nuclear Medicine and PET, University of Copenhagen, Copenhagen, Denmark. folke@mfi.ku.dk

OBJECTIVE Metabolic assessment of vascular inflammation by 2-[F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG)-PET is a promising new approach for the evaluation of the vulnerability of atherosclerotic plaques. Quantitative real-time PCR allows measurement of gene expression of markers of atherosclerotic plaque vulnerability. These techniques were applied in advanced atherosclerotic disease to relate metabolism and inflammatory activity to the gene expression profile of the vulnerable atherosclerotic plaque. METHODS Seventeen patients with clinical symptoms of cerebral vascular events (<3 months) and an additional ipsilateral internal carotid artery stenosis of greater than 60% were recruited. FDG uptake in the carotids was determined by PET/computed tomography and expressed as mean and maximal standardized uptake values (SUVmean and SUVmax). The atherosclerotic plaques were subsequently recovered by carotid endarterectomy. The gene expression of markers of vulnerability - CD68, IL-18, matrix metalloproteinase 9, cathepsin K, GLUT-1, and hexokinase type II (HK2) - were measured in plaques by quantitative PCR. RESULTS In a multivariate linear regression model, GLUT-1, CD68, cathepsin K, and HK2 gene expression remained in the final model as predictive variables of FDG accumulation calculated as SUVmean (R=0.26, P<0.0001). In addition, a multivariate linear regression model found GLUT-1, CD68, cathepsin K, and HK2 gene expression as independent predictive variables of FDG accumulation calculated as SUVmax (R=0.30, P<0.0001). CONCLUSIONS GLUT-1, HK2, CD68, and cathepsin K remained in both multivariate models and thus provided independent information regarding FDG uptake. We suggest that FDG uptake is a composite indicator of macrophage load, overall inflammatory activity and collagenolytic plaque destabilization. Accordingly, FDG-PET could prove to be an important predictor of cerebrovascular events in patients with carotid plaques.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006019 Glycolysis A metabolic process that converts GLUCOSE into two molecules of PYRUVIC ACID through a series of enzymatic reactions. Energy generated by this process is conserved in two molecules of ATP. Glycolysis is the universal catabolic pathway for glucose, free glucose, or glucose derived from complex CARBOHYDRATES, such as GLYCOGEN and STARCH. Embden-Meyerhof Pathway,Embden-Meyerhof-Parnas Pathway,Embden Meyerhof Parnas Pathway,Embden Meyerhof Pathway,Embden-Meyerhof Pathways,Pathway, Embden-Meyerhof,Pathway, Embden-Meyerhof-Parnas,Pathways, Embden-Meyerhof
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D001692 Biological Transport The movement of materials (including biochemical substances and drugs) through a biological system at the cellular level. The transport can be across cell membranes and epithelial layers. It also can occur within intracellular compartments and extracellular compartments. Transport, Biological,Biologic Transport,Transport, Biologic
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain

Related Publications

Sune Folke Pedersen, and Martin Graebe, and Anne Mette Fisker Hag, and Liselotte Højgaard, and Henrik Sillesen, and Andreas Kjaer
December 2004, Stroke,
Sune Folke Pedersen, and Martin Graebe, and Anne Mette Fisker Hag, and Liselotte Højgaard, and Henrik Sillesen, and Andreas Kjaer
April 2018, Molecular medicine reports,
Sune Folke Pedersen, and Martin Graebe, and Anne Mette Fisker Hag, and Liselotte Højgaard, and Henrik Sillesen, and Andreas Kjaer
December 2017, EJNMMI research,
Sune Folke Pedersen, and Martin Graebe, and Anne Mette Fisker Hag, and Liselotte Højgaard, and Henrik Sillesen, and Andreas Kjaer
August 2007, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics,
Sune Folke Pedersen, and Martin Graebe, and Anne Mette Fisker Hag, and Liselotte Højgaard, and Henrik Sillesen, and Andreas Kjaer
August 2017, EJNMMI research,
Sune Folke Pedersen, and Martin Graebe, and Anne Mette Fisker Hag, and Liselotte Højgaard, and Henrik Sillesen, and Andreas Kjaer
December 2004, Journal of cardiovascular pharmacology and therapeutics,
Sune Folke Pedersen, and Martin Graebe, and Anne Mette Fisker Hag, and Liselotte Højgaard, and Henrik Sillesen, and Andreas Kjaer
November 1999, American heart journal,
Sune Folke Pedersen, and Martin Graebe, and Anne Mette Fisker Hag, and Liselotte Højgaard, and Henrik Sillesen, and Andreas Kjaer
May 2008, Stroke,
Sune Folke Pedersen, and Martin Graebe, and Anne Mette Fisker Hag, and Liselotte Højgaard, and Henrik Sillesen, and Andreas Kjaer
January 2010, Expert opinion on therapeutic targets,
Sune Folke Pedersen, and Martin Graebe, and Anne Mette Fisker Hag, and Liselotte Højgaard, and Henrik Sillesen, and Andreas Kjaer
January 2012, Atherosclerosis,
Copied contents to your clipboard!